ONEVAX

EXECUTIVE OFFICERS

Mark Atkinson, Ph.D.

Mark Atkinson, Ph.D.

Founder and acting CEO

Dr. Atkinson is currently an Eminent Scholar for Diabetes Research at The University of Florida. As part of this effort, Dr. Atkinson serves as Director for The Diabetes Institute at this institution. The author of over 375 publications, Dr. Atkinson has 30 years of investigation into the field of T1D.  Dr. Atkinson has previous experience in biotech startup and drug commercialization. He has served as a consultant or on the medical/scientific board for over a dozen companies, from large pharma to small biotech, over the last decade. He holds a Ph.D. in pathology from the University of Florida and a bachelor’s in microbiology from the University of Michigan.

Ben Keselowsky, Ph.D.

Ben Keselowsky, Ph.D.

Founder and Engineering Advisor

Dr. Keselowsky has established a nationally and internationally-recognized research program in the field of biomaterials with focus on immune cell interactions with biomaterials. These works have application to biomedical technologies including designing more effective vaccines for diabetes, improving longevity of implanted devices, and decreasing immunogenicity to tissue engineered constructs. Dr. Keselowsky’s areas of expertise include using biomaterials to direct immunological processes and understanding inflammatory responses to biomaterials. Dr. Keselowsky holds a bachelor’s in chemical engineering from the University of South Florida and a Ph.D. in bioengineering from the Georgia Institute of Technology. 

Todd Brusko, Ph.D.

Todd Brusko, Ph.D.

Founder and COO

Dr. Brusko is currently appointed as an associate professor within the Department of Pathology at the University of Florida, College of Medicine.  Dr. Brusko heads up a laboratory that studies the pathogenesis of T1D and the immune system. Dr. Brusko has a Ph.D. in immunology and a bachelor’s in microbiology from the University of Florida.

 

Clive Wasserfall, M.S.

Clive Wasserfall, M.S.

Founder and CSO

Mr. Wasserfall is a Research Assistant Scientist employed at a translational program that makes extensive use of preclinical and clinical research to focus on the immunopathogenesis of T1D. Wasserfall’s M.S. is in clinical chemistry and his bachelor’s is in immunology.